Thymic stromal lymphopoietin: A promising therapeutic target for allergic diseases

W. L. Wang, H. Y. Li, M. S. Zhang, P. S. Gao, S. H. He, T. Zheng, Z. Zhu, L. F. Zhou

Research output: Contribution to journalReview article

Abstract

Thymic stromal lymphopoietin (TSLP), an interleukin 7-like cytokine, can trigger dendritic cell (DC)-mediated T-helper type 2 (Th2) inflammatory responses. Recent evidence demonstrates that cytokines TSLP and OX40 (CD134)/OX40 ligand seem to be important players in the maintenance of Th2 memory pool in the pathogenesis of asthma. Accumulating data reveal that the pathogenic T cells involved in asthma are likely to be inflammatory Th2 cells. TSLP is involved in the development of asthma through crosstalk with nuclear factor NF-κB. Progression of skin fibrosis in atopic dermatitis occurs via TSLP/TSLP receptor. TSLP-mediated dermal inflammation aggravates experimental allergic asthma. Also, TSLP polymorphisms are associated with susceptibility to asthma, atopic dermatitis, and eczema herpeticum. These findings suggest a master switch of TSLP in the initiation of allergic and adaptive inflammation through innate pathways at the epithelial cell-DC interface. The TSLP pathway is therefore a promising target for immunotherapy of allergic diseases.

Original languageEnglish (US)
Pages (from-to)18-26
Number of pages9
JournalInternational Archives of Allergy and Immunology
Volume160
Issue number1
DOIs
StatePublished - Dec 1 2012

Keywords

  • Allergy
  • Asthma
  • Dendritic cells
  • Inflammatory Th2 cells
  • NF-κB
  • Regulatory T cells
  • Thymic stromal lymphopoietin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Thymic stromal lymphopoietin: A promising therapeutic target for allergic diseases'. Together they form a unique fingerprint.

  • Cite this